Last updated on August 2018

Sorin Universal REgistry on Aortic Valve Replacement


Brief description of study

Multi-center, International, Prospective, Non comparative, Non randomized, Open label.

5,000 patients to be enrolled approximately worldwide.

The objective of this registry is to collect safety and clinical performance post market data related to the procedure and follow-up of the Sorin Group aortic valve devices in accordance with the Instructions for Use (IFU).

This observational global registry is intended to collect data without requiring any deviation from the standard of care and IFU in each participating center. The participating centers shall include those patients that have provided their informed consent to participate in this registry in accordance with the local applicable regulations.

Detailed Study Description

SURE-AVR objective is to collect post market safety and performance data collected along the procedure and the relevant follow-up with Sorin Group aortic valve devices in accordance with the IFU to further evidence the safety and efficacy in a post-approval environment. All current and future Sorin Group aortic valve devices that have obtained CE-mark or other local regulatory and/or commercial approvals may be included in the registry. During the duration of the registry,other aortic valve replacement products or current devices might receive modifications and might become commercial available. This registry allows extensions for the inclusion of new products.

This observational global registry is intended to collect data without requiring any deviation from the standard of care and IFU in each participating center. The participating centers shall include those patients that have provided their informed consent to participate in this registry following the local applicable regulations.

The data collection shall be performed as per the local standard of care and without exposing the patient to any additional risk to the treatment (s)he would normally receive.

The registry is an open-ended project:

  • Inclusions phase: open-ended
  • Follow-up phase: annually throughout 5 years (7 and 10 years are optional).

The study shall be completed after the 10-year follow-up of the last patient.

Clinical Study Identifier: NCT02679404

Find a site near you

Start Over

CHU Rennes

Rennes, France
  Connect »

Royal Brompton

London, United Kingdom
  Connect »

Bristol Royal Infirmary

Bristol, United Kingdom
  Connect »

CHU Bordeaux

Bordeaux, France
  Connect »

IKEM - Prague

Prague, Czech Republic
  Connect »

CHU Clermont-Ferrand

Clermont Ferrand, France
  Connect »

Princeton Baptist Med Center

Birmingham, AL United States
  Connect »

IRCCS Policlinico San Donato

San Donato Milanese, Italy
  Connect »

River City Clinical Research

Jacksonville, FL United States
  Connect »

Mount Carmel Hospital

Columbus, OH United States
  Connect »

UMC Groningen

Groningen, Netherlands
  Connect »

Vusch - Kosice

Košice, Slovakia
  Connect »

CHU La Timone

Marseille, France
  Connect »

CHR Namur

Namur, Belgium
  Connect »

Hammersmith Hospital

London, United Kingdom
  Connect »

UCL St Luc

Brussels, Belgium
  Connect »

Blackpool Teaching Hospital

Blackpool, United Kingdom
  Connect »

Columbia University Hospital

New York, NY United States
  Connect »

CHU Li ge

Liège, Belgium
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.